BiVictriX Therapeutics appoint Dr. Michael Carter as new non-executive director

Acceleris client company BiVictriX Therapeutics are delighted to announce the appointment of Dr. Michael Carter as their new Non-Executive Director. Dr. Michael brings a wealth of experience to BiVictriX and will assist in the next phase of the development of the business.

Dr. MICHAEL G CARTER MB ChB, FRCP (Edin), B.Pharm, DipPharmMed, FRPharm.Soc, FFPM.

  • 45 Years at senior level in the global Pharmaceutical, Biotechnology and Life Sciences Venture Capital industries.

  • Actively involved in the development and introduction of over 20 innovative new medicines to the world healthcare market, most achieving billion dollar peak year sales status, a majority being cancer focussed.

  • 25years Board level experience with I.C.I Pharmaceuticals (Astra Zeneca) and Roche Products, involving both global clinical development Phase 1 -IV and subsequent global marketing responsibility.

  • A member of UK Medicines Commission for 10 years, twice reappointed by the Minister of Health.

  • Awarded Sunday Times Non- Executive Director of the Year 2006 for Private Equity, the first award of such.

  • In the last 20 years Non- Executive Director/ Chair of circa 20 Biotechnology companies both US and EU with divested returns of over  $7Bn.

  • The first Venture Partner at SV Health Investors 1998-2016 and presently on the Investment Committee and Senior Advisory Board of Healthcare Royalty Partners.

NewsPatrick Molyneux